Long-term Outcomes of Cetuximab in Larynx Preservation Trial
Author Information
Author(s): Wichmann Gunnar, Wald Theresa, Zebralla Veit, Stoehr Matthaeus, Pirlich Markus, Wiegand Susanne, Kunz Viktor, Dietz Andreas
Primary Institution: University Hospital Leipzig
Hypothesis
Does the addition of cetuximab to induction chemotherapy improve long-term outcomes in patients with advanced laryngeal/hypopharyngeal cancer?
Conclusion
The long-term follow-up data show that patients receiving cetuximab had superior overall survival compared to those who did not.
Supporting Evidence
- Patients receiving cetuximab had improved overall survival at 125 months.
- Non-cancer-related survival was significantly better in the cetuximab group.
- Patients in arm B had a higher percentage of surviving with a functioning larynx.
Takeaway
This study found that adding a medicine called cetuximab to treatment helps patients with throat cancer live longer and keep their voice.
Methodology
Patients were treated with induction chemotherapy followed by response evaluation and radiotherapy, with some receiving cetuximab.
Potential Biases
The study may have selection bias due to the small number of patients and the specific inclusion criteria.
Limitations
The study had a small sample size and was conducted at a single center, which may limit the generalizability of the results.
Participant Demographics
{"age_distribution":{"under_50":14,"50_to_59":23,"60_to_69":10,"70_and_over":5},"sex_distribution":{"male":44,"female":8},"tobacco_use":{"0_pack_years":0,"30_or_less_pack_years":25,"more_than_30_pack_years":27}}
Statistical Information
P-Value
0.023
Confidence Interval
95% CI 46.1–82.3 for arm A, 95% CI 75.7–108.7 for arm B
Statistical Significance
p = 0.023
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website